# Safety, Tolerability and Immunogenicity of Two Doses of Adjuvanted Monovalent Influenza Vaccine Administered to Healthy Adult and Elderly Subjects

> **NCT00841763** · PHASE3 · COMPLETED · sponsor: **Novartis** · enrollment: 3647 (actual)

## Conditions studied

- Pandemic Influenza Disease

## Interventions

- **BIOLOGICAL:** Placebo (PL)
- **BIOLOGICAL:** Trivalent influenza virus vaccine (TIV)
- **BIOLOGICAL:** Adjuvanted monovalent influenza virus vaccine (aH5N1)
- **BIOLOGICAL:** Adjuvanted trivalent influenza virus vaccine (aTIV)

## Key facts

- **NCT ID:** NCT00841763
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2009-04
- **Final completion:** 2009-11
- **Target enrollment:** 3647 (ACTUAL)
- **Last updated:** 2021-04-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00841763

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00841763, "Safety, Tolerability and Immunogenicity of Two Doses of Adjuvanted Monovalent Influenza Vaccine Administered to Healthy Adult and Elderly Subjects". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00841763. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*